Differences in SARS-CoV-2 antibodies depending on age, blood group, and sex in a Swedish blood donor cohort

References

• The Public Health Agency of Sweden. Analys av första covid-19-vågen– produktion, köer och väntetider i vården. 2020 [cited 2023 16 May 2023]. Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ovrigt/2020-11-7065.pdf.
   Google Scholar
• Castro Dopico X, Muschiol S, Christian M, et al. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden. J Intern Med. 2021;290(3):666–676. doi: 10.1111/joim.13304.
   PubMed Web of Science ®Google Scholar
• Beser J, Galanis I, Enkirch T, et al. Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021. Sci Rep. 2022;12(1):10816. doi: 10.1038/s41598-022-15183-w.
   PubMed Web of Science ®Google Scholar
• Sjörs Dahlman A, Anund A. Seroprevalence of SARS-CoV-2 antibodies among public transport workers in Sweden. J Transp Health. 2022;27:101508. doi: 10.1016/j.jth.2022.101508.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK. Epidemiologic surveillance for controlling Covid-19 pandemic: types, challenges and implications. J Infect Public Health. 2020;13(11):1630–1638. doi: 10.1016/j.jiph.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Peeling RW, Heymann DL, Teo YY, et al. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399(10326):757–768.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J. COVID-19 convalescent plasma. 2021. Available from: https://www.fda.gov/media/141477/download.
   Google Scholar
• European Commission. An EU programme of COVID-19 convalescent plasma collection and transfusion - Guidance on collection, testing, processing, storage, distribution and monitored use version 4.0. Brussels: European Commission; 2021.
   Google Scholar
• Lamontagne F, Agarwal A, Rochwerg B, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
   PubMedGoogle Scholar
• Terpos E, Stellas D, Rosati M, et al. SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. Eur J Intern Med. 2021. 2021;89:87–96.
   PubMed Web of Science ®Google Scholar
• Basto-Abreu A, Carnalla M, Torres-Ibarra L, et al. Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico. Nat Commun. 2022;13(1):589. doi: 10.1038/s41467-022-28232-9.
   PubMed Web of Science ®Google Scholar
• Wiegand RE, Deng Y, Deng X, et al. Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District Of Columbia, United States-October 25, 2020-February 26, 2022. Lancet Reg Health Am. 2023;18:100403.
   PubMedGoogle Scholar
• Ekelund O, Ekblom K, Somajo S, et al. High-throughput immunoassays for SARS-CoV-2 - considerable differences in performance when comparing three methods. Infect Dis (Lond). 2021;53(10):805–810.
   PubMed Web of Science ®Google Scholar
• Perkmann T, Perkmann-Nagele N, Breyer MK, et al. Side-by-Side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity. Clin Chem. 2020;66(11):1405–1413. doi: 10.1093/clinchem/hvaa198.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhu K, Liu X, et al. The protection of naturally acquired antibodies Against subsequent SARS-CoV-2 infection: a systematic review and meta-analysis. Emerg Microbes Infect. 2022;11:793–803.
   PubMed Web of Science ®Google Scholar
• Atsma F, Veldhuizen I, Verbeek A, et al. Healthy donor effect: its magnitude in health research among blood donors. Transfusion. 2011;51(8):1820–1828. doi: 10.1111/j.1537-2995.2010.03055.x.
   PubMed Web of Science ®Google Scholar
• Kim Y, Latz CA, DeCarlo CS, et al. Relationship between blood type and outcomes following COVID-19 infection. Semin Vasc Surg. 2021;34:125–131.
   PubMed Web of Science ®Google Scholar
• Hindawi S, Daghistani S, Elgemmezi T, et al. Association of blood group with COVID-19 disease susceptibility and severity in Saudi Arabia. Transfusion. 2023;63 Suppl 1:S3–S9. doi: 10.1111/trf.17202.
   PubMed Web of Science ®Google Scholar
• Palmos AB, Millischer V, Menon DK, et al. Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19. PLoS Genet. 2022;18(3):e1010042. doi: 10.1371/journal.pgen.1010042.
   PubMed Web of Science ®Google Scholar
• Goel R, Bloch EM, Pirenne F, et al. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. Vox Sang 2021;116:849–861.
   Google Scholar
• Jawdat D, Hajeer A, Massadeh S, et al. Correlation between ABO blood group phenotype and the risk of COVID-19 infection and severity of disease in a Saudi Arabian cohort. J Epidemiol Glob Health. 2022;12(1):85–91. doi: 10.1007/s44197-021-00023-3.
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6(1):104. doi: 10.1038/s41541-021-00369-6.
   PubMed Web of Science ®Google Scholar
• Collaborators C-EM. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020. Lancet. 2022;399(21):1513–1536.
   PubMedGoogle Scholar
• Wixe S, Lobo J, Mellander C, et al. Evidence of COVID-19 fatalities in swedish neighborhoods from a full population study. Sci Rep. 2024;14(1):2998. doi: 10.1038/s41598-024-52988-3.
   PubMed Web of Science ®Google Scholar
• Marziano V, Guzzetta G, Menegale F, et al. Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality. Influenza Other Respir Viruses. 2023;17:e13181.
   PubMed Web of Science ®Google Scholar
• Valenti L, Pelusi S, Cherubini A, et al. Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion. 2021;61(12):3381–3389. doi: 10.1111/trf.16693.
   PubMed Web of Science ®Google Scholar
• Siller A, Seekircher L, Wachter GA, et al. Seroprevalence, waning and correlates of Anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: large-Scale study of 35,193 blood donors conducted between June 2020 and September 2021. Viruses. 2022;14(3):568. doi: 10.3390/v14030568.
   PubMed Web of Science ®Google Scholar
• O’Brien SF, Caffrey N, Yi QL, et al. SARS-CoV-2 seroprevalence among Canadian blood donors: the advance of Omicron. Viruses. 2022;14(11):2336. doi: 10.3390/v14112336.
   PubMed Web of Science ®Google Scholar
• Prete CA, Jr., Buss LF, Whittaker C, et al. SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: a serial cross-sectional study. Elife. 2022;11:e78233. doi: 10.7554/eLife.78233.
   PubMed Web of Science ®Google Scholar
• Hayes C, Rubenstein W, Gibb D, et al. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations. Transfusion. 2021;61(8):2245–2249. doi: 10.1111/trf.16524.
   PubMed Web of Science ®Google Scholar
• Chaves DG, Takahashi RHC, Campelo F, et al. SARS-CoV-2 IgG seroprevalence among blood donors as a monitor of the COVID-19 epidemic, Brazil. Emerg Infect Dis. 2022;28:734–742.
   PubMed Web of Science ®Google Scholar
• Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfus. 2021;19:181–189.
   PubMed Web of Science ®Google Scholar
• Slot E, Hogema BM, Reusken C, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in The Netherlands. Nat Commun. 2020;11(1):5744. doi: 10.1038/s41467-020-19481-7.
   PubMed Web of Science ®Google Scholar
• Stone M, Di Germanio C, Wright DJ, et al. Use of US blood donors for national serosurveillance of severe acute respiratory syndrome coronavirus 2 antibodies: basis for an expanded national donor serosurveillance program. Clin Infect Dis. 2022;74(5):871–881. doi: 10.1093/cid/ciab537.
   PubMed Web of Science ®Google Scholar
• Vassallo RR, Dumont LJ, Bravo MD, et al. Progression and predictors of SARS-CoV-2 antibody seroreactivity In US blood donors. Transfus Med Rev. 2021;35:8–15.
   PubMed Web of Science ®Google Scholar
• Pereira E, Felipe S, de Freitas R, et al. ABO blood group and link to COVID-19: a comprehensive review of the reported associations and their possible underlying mechanisms. Microb Pathog. 2022;169:105658.
   PubMed Web of Science ®Google Scholar
• Deschasaux-Tanguy M, Szabo de Edelenyi F, Druesne-Pecollo N, et al. ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study. Sci Rep. 2023;13(1):4775. doi: 10.1038/s41598-023-30714-9.
   PubMed Web of Science ®Google Scholar
• Mortensen SJ, Gjerding LAM, Exsteen MB, et al. Reduced susceptibility to COVID-19 associated with ABO blood group and pre-existing anti-A and anti-B antibodies. Immunobiology. 2023;228(4):152399. doi: 10.1016/j.imbio.2023.152399.
   PubMed Web of Science ®Google Scholar
• Wu SC, Arthur CM, Jan HM, et al. Blood group A enhances SARS-CoV-2 infection. Blood. 2023;142(8):742–747. doi: 10.1182/blood.2022018903.
   PubMed Web of Science ®Google Scholar
• Tamayo-Velasco A, Penarrubia-Ponce MJ, Alvarez FJ, et al. ABO blood system and COVID-19 susceptibility: anti-A and anti-B antibodies are the key points. Front Med (Lausanne). 2022;9:882477. doi: 10.3389/fmed.2022.882477.
   PubMed Web of Science ®Google Scholar
• Hasan M, Moiz B, Qaiser S, et al. IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi. PLoS One. 2022;17(8):e0271259. doi: 10.1371/journal.pone.0271259.
   PubMed Web of Science ®Google Scholar
• Muniz-Diaz E, Llopis J, Parra R, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfus. 2021;19:54–63.
   PubMed Web of Science ®Google Scholar
• Davitt E, Davitt C, Mazer MB, et al. COVID-19 disease and immune dysregulation. Best Pract Res Clin Haematol. 2022;35:101401.
   PubMed Web of Science ®Google Scholar
• Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2:e240–e249.
   PubMedGoogle Scholar
• Markmann AJ, Giallourou N, Bhowmik DR, et al. Sex disparities and neutralizing-antibody durability to SARS-CoV-2 infection in convalescent individuals. mSphere. 2021;6(5):e0027521. doi: 10.1128/mSphere.00736-21.
   PubMed Web of Science ®Google Scholar
• Navaratnam AMD, Shrotri M, Nguyen V, et al. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort. Int J Infect Dis. 2022;123:104–111.
   PubMed Web of Science ®Google Scholar
• Nunhofer V, Weidner L, Hoeggerl AD, et al. Persistence of naturally acquired and functional SARS-CoV-2 antibodies in blood donors one year after infection. Viruses. 2022;14(3):637. doi: 10.3390/v14030637.
   PubMed Web of Science ®Google Scholar
• Bloch EM, Patel EU, Marshall C, et al. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. Vox Sang. 2021;116:766–773.
   PubMed Web of Science ®Google Scholar
• Martin MC, Jimenez A, Ortega N, et al. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors. PLoS One. 2022;17(2):e0264124. doi: 10.1371/journal.pone.0264124.
   PubMed Web of Science ®Google Scholar
• Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 spike versus nucleoprotein antibody responses impact the estimates of infections in population-based seroprevalence studies. J Virol. 2021;95(3):e01828-20. doi: 10.1128/JVI.01828-20.
   PubMed Web of Science ®Google Scholar
• Germain M, Lewin A, Bazin R, et al. Cohort profile: a Quebec-based plasma donor biobank to study COVID-19 immunity (PlasCoV). BMJ Open. 2023;13(2):e068803. doi: 10.1136/bmjopen-2022-068803.
   PubMed Web of Science ®Google Scholar
• Gallian P, Hozé N, Brisbarre N, et al. SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021. iScience. 2023;26(4):106222. doi: 10.1016/j.isci.2023.106222.
   PubMed Web of Science ®Google Scholar
• Forgacs D, Silva-Moraes V, Sautto GA, et al. The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination. Vaccines (Basel). 2022;10(5):696. doi: 10.3390/vaccines10050696.
   PubMed Web of Science ®Google Scholar
• Castillo-Olivares J, Wells DA, Ferrari M, et al. Analysis of serological biomarkers of SARS-CoV-2 infection in convalescent samples from severe, moderate and mild COVID-19 cases. Front Immunol. 2021;12:748291. doi: 10.3389/fimmu.2021.748291.
   PubMed Web of Science ®Google Scholar
• Sudhakar R, Dontamala S, Bingi TC, et al. A comparative study of antibody response, virus neutralization efficiency & metabolites in SARS-CoV-2-infected adults & children. Indian J Med Res. 2022;156(4&5):659–668. doi: 10.4103/ijmr.ijmr_3475_21.
   PubMed Web of Science ®Google Scholar